Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: The Company manufactures and distributes apparatus, instruments, and consumables for life science research. Operations are divided into continuing operations (Apparatus and Instrumentation Business) and discontinued operations (Capital Equipment Business segment, which is held for sale).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2007 |
Nine Months Ended Sep 30, 2007 |
Nine Months Ended Sep 30, 2006 |
|---|---|---|---|
| Revenues | $19,353 | $58,878 | $54,498 |
| Gross Profit | $9,276 | $28,681 | $27,485 |
| Gross Margin % | 47.9% | 48.7% | 50.4% |
| Operating Income | $2,000 | $6,817 | $6,393 |
| Income from Continuing Ops | $1,518 | $5,275 | $4,667 |
| Discontinued Ops (Loss) | $(299) | $(5,326) | $(4,630) |
| Net Income (Loss) | $1,219 | $(51) | $37 |
| Cash and Equivalents | $15,063 (as of Sep 30, 2007) | ||
| Long-Term Debt | $2,807 (as of Sep 30, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues from continuing operations increased 8.0% for the nine months ended September 30, 2007, compared to the prior year. This was driven by favorable foreign exchange rates ($2.3 million impact), the acquisition of Anthos product lines, and strong sales in the US and UK markets.
- Margin Compression: Gross margin percentage decreased from 50.4% to 48.7% for the nine-month period. Management attributes this to a higher proportion of sales from lower-margin Anthos products and under-absorbed manufacturing costs.
- Discontinued Operations: The loss from discontinued operations widened to $5.3 million for the nine months ended September 30, 2007, compared to $4.6 million in the prior year. This increase included $2.9 million in asset impairment charges related to the Capital Equipment Business segment held for sale.
- Net Income Volatility: While income from continuing operations improved, the net loss for the nine-month period was $(51) thousand, compared to a net income of $37 thousand in the prior year, primarily due to the losses from discontinued operations.
Outlook, Risks, and Management Commentary
- Divestiture of Capital Equipment Business: The Company is actively seeking to divest its Capital Equipment Business segment. A proposed agreement exists but is not definitive. The sale requires lender consent; failure to obtain consent could trigger a default on the credit facility.
- GE Healthcare Distribution Agreement: On October 1, 2007, GE Healthcare notified the Company of its intent not to renew the distribution agreement, which expires September 28, 2008. The Company is negotiating a new agreement, but failure to do so could adversely impact revenues.
- Recent Acquisition: On October 11, 2007, the Company acquired Panlab s.l. of Spain for approximately $5.0 million in cash to expand its presence in the neuroscience research market.
- Liquidity: The Company maintains a $20.0 million revolving credit facility with $17.2 million available. Management expects current cash, operating cash flow, and debt capacity to be sufficient for operations for at least the next 12 months.
- Foreign Exchange: The weakening of the U.S. dollar against foreign currencies (specifically the Euro and British Pound) positively impacted reported revenues and earnings.
Investor Verification Checklist
- GE Healthcare Renewal: Verify the status of negotiations for the new distribution agreement with GE Healthcare, given the non-renewal notice.
- Divestiture Progress: Monitor the definitive agreement status for the Capital Equipment Business segment and the associated lender consent requirements.
- Margin Trends: Assess whether the gross margin compression from lower-margin product mixes (Anthos) is a temporary integration issue or a structural shift.
- Impairment Charges: Review future potential for additional impairment charges related to the Capital Equipment Business segment if the sale is delayed or terms change.
- Debt Covenants: Confirm continued compliance with financial covenants, particularly regarding the sale of the discontinued segment.